Skip to content

The efficacy, safety and mechanism of esketamine vs electroconvulsive therapy in the treatment of suicidal risk of patients with major depressive episode

The efficacy, safety and mechanism of esketamine vs electroconvulsive therapy in the treatment of suicidal risk of patients with major depressive episode

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071697
Enrollment
Unknown
Registered
2023-05-23
Start date
2023-05-23
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive episode with suicidal ideation

Interventions

Esketamine group:intravenous infusion of esketamine (0.5mg/kg)
MECT group:MECT

Sponsors

The Affiliated Brain Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 13-85 years old,right-handed, inpatient treatment at the Affiliated Brain Hospital of Guangzhou Medical University; 2. Meet the diagnostic criteria for Major Depressive Disorder or bipolar disorder with Current or most recent episode depressed in the American Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV); 3. HAMD-17 items = 17 points; 4. Patients with current suicidal ideation, and the scores of item 4 or item 5 of Beck Scale for Suicide Ideation (SSI) = 2; 5.Subjects with primary school education or above; 6.The subjects who understand the content of the study are willing to join the study and sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1.Diagnosed with hypomanie episode or manic episode in 6 months, or the current YMRS >7 points; 2.Diagnosed with other mental disorders diagnosed by DSM-4, including schizophrenia, substance related disorder and addiction disorder, autism spectrum dsorder, intellectual disabilities(except anxiety disorder); 3.Patients with high suicide risk: had suicidal behavior (defined as self injuring behavior with intention to die) in the past six months, or the researchers judged that they had high suicide risk,or the answer of item 5 of a clinician-rated Columbia suicide severity rating scale (C-SSRS) ,whether they have suicidal ideation with specific plans and intentions,is yes; 4.Refractory hypertension, hypothyroidism or hyperthyroidism, vitamin B12 or folic acid deficiency, syphilis infection; 5.History of nervous system disease, like epilepsy, stroke, dementia, and brain trauma; 6.Suffering from major physical diseases such as heart, lungs, liver, and kidney, and cannot tolerate this study; 7.Past history of esketamine allergy; 8.Patients with angle-closure glaucoma. 9.Bladder irritation symptoms (frequency of urination, urgency of urination, pain in urination) that require clinical intervention; 10.Body mass index (BMI) 40kg/m2;, or

Design outcomes

Primary

MeasureTime frame
Beck Scale for Suicide Ideation;

Secondary

MeasureTime frame
Montgomery-Asberg Depression Rating Scale;Hamilton Depression Scale;Hamilton Anxiety Scale;Snaim-Hamilton Pleasure scale;Dimensional Anhedonia Rating Scale;The Clinician Administered Dissociative States Scale;

Countries

China

Contacts

Public ContactYuping Ning

The Affiliated Brain Hospital of Guangzhou Medical University

ningjeny@126.com+86 20 8157 0720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026